Berenberg Bank initiated coverage on shares of Oncimmune (LON:ONC) in a research report report published on Friday. The firm issued a buy rating and a GBX 169 ($2.29) target price on the stock.

Oncimmune (LON ONC) traded down GBX 2.49 ($0.03) during trading on Friday, reaching GBX 127.51 ($1.73). 6,678 shares of the company traded hands, compared to its average volume of 8,944. Oncimmune has a 12-month low of GBX 100 ($1.36) and a 12-month high of GBX 150 ($2.03). The firm has a market cap of $70.41 and a P/E ratio of -1,275.10.

COPYRIGHT VIOLATION NOTICE: “Oncimmune (ONC) Receives New Coverage from Analysts at Berenberg Bank” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at

Oncimmune Company Profile

Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types.

Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with's FREE daily email newsletter.